Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) — Market Cap & Net Worth
Market Cap & Net Worth: Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) has a market capitalization of $5.84 Billion ($5.84 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3221 globally and #1140 in its home market, demonstrating a -5.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rhythm Pharmaceuticals Inc's stock price $96.77 by its total outstanding shares 68285039 (68.29 Million). Also see Rhythm Pharmaceuticals Inc assets under control for a full breakdown of the balance sheet.
Rhythm Pharmaceuticals Inc Market Cap History: 2017 to 2026
Rhythm Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows growth from $1.98 Billion to $6.61 Billion (13.98% CAGR). Also see how efficiently does Rhythm Pharmaceuticals Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Rhythm Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.22% | #81 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.01% | #367 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.31% | #54 of 263 |
Weight: Rhythm Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rhythm Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rhythm Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Rhythm Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
38.52x
Rhythm Pharmaceuticals Inc's market cap is 38.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.03 Billion | $35.00K | -$130.73 Million | 58003.26x | N/A |
| 2021 | $681.48 Million | $3.15 Million | -$68.01 Million | 216.07x | N/A |
| 2022 | $1.99 Billion | $23.64 Million | -$181.12 Million | 84.12x | N/A |
| 2023 | $3.14 Billion | $77.43 Million | -$184.68 Million | 40.54x | N/A |
| 2024 | $3.82 Billion | $130.13 Million | -$260.60 Million | 29.38x | N/A |
| 2025 | $7.31 Billion | $189.76 Million | -$196.54 Million | 38.52x | N/A |
Competitor Companies of RYTM by Market Capitalization
Companies near Rhythm Pharmaceuticals Inc in the global market cap rankings as of September 16, 2026. Review RYTM goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Rhythm Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Rhythm Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Rhythm Pharmaceuticals Inc's market cap moved from $1.98 Billion to $ 6.61 Billion, with a yearly change of 13.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.61 Billion | -9.59% |
| 2025 | $7.31 Billion | +91.21% |
| 2024 | $3.82 Billion | +21.78% |
| 2023 | $3.14 Billion | +57.86% |
| 2022 | $1.99 Billion | +191.78% |
| 2021 | $681.48 Million | -66.43% |
| 2020 | $2.03 Billion | +29.49% |
| 2019 | $1.57 Billion | -14.58% |
| 2018 | $1.84 Billion | -7.50% |
| 2017 | $1.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Rhythm Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.84 Billion USD |
| MoneyControl | $5.84 Billion USD |
| MarketWatch | $5.84 Billion USD |
| marketcap.company | $5.84 Billion USD |
| Reuters | $5.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more